Canaccord Genuity maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and significantly increased the price target to $45 from the previous $22. The adjustment reflects the firm's continued ...
Maximize ad relevance by layering audiences in Google Ads. Combine remarketing, in-market segments, and more to refine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback